New immunosuppressive agents: Expectations and controversies

Transplantation

Volumn 75, Issue 6, 2003, Pages 741-742

  Alsina, J ^a   Grinyo J M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 3; CREATININE; CYCLOSPORIN; GELATINASE A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA; IMMUNOSUPPRESSIVE AGENT;

CELL PROLIFERATION; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; ENDOTHELIUM CELL; FIBROBLAST; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; NEPHROTOXICITY; NOTE; PRIORITY JOURNAL; REPERFUSION INJURY; SMOOTH MUSCLE FIBER; GRAFT REJECTION; KIDNEY TRANSPLANTATION;

CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS;

EID: 0037468694     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000046766.12404.F9/     Document Type: Note

References (5)

1. Kreis H. New strategies to reduce nephrotoxicity. Transplantation 2001: 72(suppl): 99-104.
2. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001;12:1059-1071.
3. MacDonald A. Improving tolerability of immunosuppressive regimens. Transplantation 2001; 72(suppl): 105-112.
4. Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000; 70: 969-975.
5. Johnson RWG, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-786.03